Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Immunological profiling of multi-food allergen immunotherapy assessing humoral and cellular activation profiles

FY 2020-21

Summary
Food allergy affects up to 8% of children, many of whom suffer from multiple food allergies. Oral immunotherapy (OIT) to one food at a time is emerging as a food allergy treatment. During an OIT, increments of the symptom eliciting food are applied over time to achieve desensitization. This procedure ultimately increases the amount of allergen the child can eat without inciting a reaction. However, the current model of OIT focuses on the introduction of large amounts of a single food, requires many hospital visits, and allergic reactions are frequent. Two investigator-initiated OIT clinical trials investigate treatment options to address these side effects to make simultaneous treatment of multiple food allergies safe and efficient. The Low Dose Multi-OIT for Food Allergy (LoMO, NCT03799328) study investigates the possibility of low dose multi-food immunotherapy (30mg instead of 3-5g). The CIHR-funded 15 months, double-Blind, randomized controlled trial comparing 20 weeks of 2 dosages of Omalizumab, an anti-IgE biologic, to placebo to accelerate a symptom-driven Oral immunotherapy schedule in subjects aged 6-25 years with Multiple food allergies (BOOM; NCT04045301). The immunological mechanisms of OIT are not well understood, and markers that predict favourable outcomes are needed. The project's objective is to utilize flow and mass cytometry to delineate changes in allergen-specific innate cell activation profiles. Patterns of immunological changes, such as IgE downstream activation of effector cells, will help identify signatures associated with symptom-free treatment responses. Findings will help refine current treatment approaches to improve the chances of a successful outcome while reducing the incidence of adverse anaphylactic events during OIT.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449815
Name
Li Carmen H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Immunological profiling of multi-food allergen immunotherapy assessing humoral and cellular activation profiles
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Ige; Desensitization; Efficacy; Food Allergy; Omalizumab; Oral Immunotherapy; Pediatrics; Randomized Controlled Trial; Safety
Abstract
Food allergy affects up to 8% of children, many of whom suffer from multiple food allergies. Oral immunotherapy (OIT) to one food at a time is emerging as a food allergy treatment. During an OIT, increments of the symptom eliciting food are applied over time to achieve desensitization. This procedure ultimately increases the amount of allergen the child can eat without inciting a reaction. However, the current model of OIT focuses on the introduction of large amounts of a single food, requires many hospital visits, and allergic reactions are frequent. Two investigator-initiated OIT clinical trials investigate treatment options to address these side effects to make simultaneous treatment of multiple food allergies safe and efficient. The Low Dose Multi-OIT for Food Allergy (LoMO, NCT03799328) study investigates the possibility of low dose multi-food immunotherapy (30mg instead of 3-5g). The CIHR-funded 15 months, double-Blind, randomized controlled trial comparing 20 weeks of 2 dosages of Omalizumab, an anti-IgE biologic, to placebo to accelerate a symptom-driven Oral immunotherapy schedule in subjects aged 6-25 years with Multiple food allergies (BOOM; NCT04045301). The immunological mechanisms of OIT are not well understood, and markers that predict favourable outcomes are needed. The project's objective is to utilize flow and mass cytometry to delineate changes in allergen-specific innate cell activation profiles. Patterns of immunological changes, such as IgE downstream activation of effector cells, will help identify signatures associated with symptom-free treatment responses. Findings will help refine current treatment approaches to improve the chances of a successful outcome while reducing the incidence of adverse anaphylactic events during OIT.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Carmen H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~